Lobe Sciences is a listed (CSE) Canadian company with a focus on treating traumatic brain injury (TBI). It is led by pioneering scientists, engineers, and physicians focused on investigating, researching and developing treatments for brain health through alternative and nontraditional medicines and the latest technologies.
Lobe Sciences
Lobe Sciences is exploring the potential of psychedelics to treat a range of neurological disorders including mild-traumatic brain injury (mTBI) and PTSD. The company are investigating the safety and efficacy of psilocybin and MDMA when each is given in tandem with N-acetylcysteine (NAC), a derivative of the amino acid L-cystine which has antioxidant and anti-inflammatory properties.
The company’s mission is to find and build innovative new methods, medicines and devices that offer new pathways to treat brain injuries and neurological disorders to improve brain health and wellness.
Activities
B2C
Pharmaceutical
Biotech
Drug Discovery
Compounds of Interest
Psilocybin
Topics of Interest
Traumatic Brain Injury
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Lobe Sciences Successfully Completes Proof-of-Concept of Proprietary NasalMist Device (Press Release, 18 February 2021)
Lobe Sciences announces the completion of a proof-of-concept nasal spray which could be used to deliver microdoses of psilocybin and/or NAC for their TBI treatment.
Lobe Sciences Appoints Charles Grob, MD to Scientific Advisory Board (Press Release, 28 June 2021)
Lobe Sciences announces the appointment of Charles Grob to its scientific advisory board.
Lobe Sciences Announces Data Demonstrating That Its Combination Therapeutic Candidates are Significantly More Effective Than Monotherapy in mTBI and PTSD (Press Release, 28 September 2021)
Lobe Sciences announces that treatment of NAC plus psilocybin is more effective in treating mild traumatic brain injury in mice.
Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD (Press Release, 21 December 2021)
Lobe Sciences announces the PCT (Patent Cooperation Treaty) patent application for their method of treating mTBI and PTSD.